Inflammatory cardiomyopathy is a common condition characterized by cardiac immune cell infiltration. It can be complicated by heart failure and is associated with adverse outcomes.
1 Although the condition is predominantly caused by viral infections, a broad variety of factors, including systemic immune disorders and the toxic effects of medications, can produce tissue inflammation and fibrosis leading to impaired cardiac function.
2 Inflammatory cardiomyopathy has recently been observed in autopsies of patients with SARS-CoV-2 infection.
3 Furthermore, high cardiac troponin levels indicative of myocardial injury have been frequently reported among hospitalized patients with SARS-CoV-2 infection,
4 and myocardial inflammation may persist in individuals who recovered from this disease.
5 Thus, SARS-CoV-2 infection may be associated with inflammatory cardiomyopathy; however, the molecular signatures underlying this condition have remained elusive.